1. Executive Summary
• 1.1 Key Findings
• 1.2 Market Snapshot: Value, Units and Blended ASP, 2024, 2025 and 2032
• 1.3 Analyst Viewpoint
2. Research Methodology
• 2.1 Research Scope and Market Definition
• 2.2 Data Sources: Primary and Secondary Research
• 2.3 Market Sizing Approach: Procedure-Based and Vendor Revenue Models
• 2.4 Unit Volume and ASP Estimation
• 2.5 Forecasting Assumptions and Data Triangulation
• 2.6 Abbreviations
3. U.S. Vascular Closure Devices Market Outlook
• 3.1 Market Value, 2020–2032 (US$ Million)
• 3.2 Year-on-Year Growth, 2021–2032
• 3.3 Unit Volume, 2020–2032 (Million Units)
• 3.4 Blended Average Selling Price, 2020–2032
4. Market Dynamics
• 4.1 Drivers
• 4.1.1 Growth of Structural Heart and Electrophysiology Procedures
• 4.1.2 Same-Day Discharge and Laboratory Throughput
• 4.1.3 Growth in Peripheral and Venous Interventions
• 4.2 Restraints
• 4.2.1 Femoral-to-Radial Access Shift
• 4.2.2 GPO Pricing Pressure
• 4.3 Opportunities
• 4.3.1 Large-Bore Arterial Closure
• 4.3.2 Venous Closure for Electrophysiology
• 4.3.3 Ambulatory Surgery Centers and Office-Based Labs
• 4.4 Challenges
• 4.4.1 Access Site Complications and Clinical Evidence Requirements
• 4.4.2 Procedure Technology Shifts (e.g., Pulsed Field Ablation)
5. Hospital Economics and Adoption Analysis
• 5.1 Closure Device vs Manual Compression Economics
• 5.2 Reimbursement Context
• 5.3 Purchasing and Contracting Trends
6. Price-Mix Analysis
• 6.1 Value Share vs Unit Share by Device Type
• 6.2 Average Selling Price by Device Type, 2020–2032
• 6.3 Sources of Incremental Growth, 2024–2032
7. Market Analysis by Type (Value and Units, 2020–2032)
• 7.1 Passive Approximators
• 7.1.1 Collagen Plugs
• 7.1.2 Sealant or Gel-based Devices
• 7.1.3 Compression Assist Devices
• 7.2 Active Approximators
• 7.2.1 Suture-based Devices
• 7.2.2 Clip-based Devices
• 7.3 External Hemostatic Devices
8. Market Analysis by Access (Value, 2020–2032)
• 8.1 Femoral Access
• 8.2 Radial Access
9. Market Analysis by Procedure (Value, 2020–2032)
• 9.1 Interventional Cardiology
• 9.2 Interventional Radiology/Vascular Surgery
10. Regulatory Landscape
• 10.1 FDA Premarket Approval Pathway for Closure Devices
• 10.2 Recent Approvals and Label Expansions
• 10.3 Post-Market Surveillance and Recalls
11. Competitive Landscape
• 11.1 Market Structure and Concentration
• 11.2 Recent Acquisitions, Divestitures and Ownership Changes
• 11.3 Epignosis Insights Competitive Assessment Framework (EICAF)
• 11.4 EICAF Scoring Method and Company Rankings
12. Company Profiles
• 12.1 Abbott
• 12.2 Terumo
• 12.3 Haemonetics (incl. Vivasure Medical)
• 12.4 Cordis
• 12.5 Teleflex
• 12.6 Merit Medical Systems
• 12.7 Other Emerging Players
• Each profile: Company Overview, Closure Portfolio, Clinical Evidence, Financial Snapshot, Recent Developments
13. Strategic Recommendations
• 13.1 For Device Manufacturers
• 13.2 For Hospitals and Purchasing Organizations
• 13.3 For Investors
14. Appendix
• 14.1 List of Tables
• 14.2 List of Figures
• 14.3 Disclaimer